ATP6V1G1P7

Across TCGA pan-cancer cohorts, ATP6V1G1P7 RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated ATP6V1G1P7 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ATP6V1G1P7 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP6V1G1P7 expression acts as an unfavorable survival marker.

STAD, ESCA, and TGCT are the cancer types where ATP6V1G1P7 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	All	0.311	0.734	<.001	72	view →
ESCA	OS	Tertile	IV	0.095	0.512	.008	36	view →
TGCT	DFS	Tertile	II,III,IV	0.015	0.919	<.001	36	view →
BLCA	OS	Tertile	IV	0.133	0.589	.006	18	view →
DLBC	DFS	Tertile	All	0.111	0.644	.020	18	view →
PRAD	DFS	Tertile	All	0.113	0.886	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATP6V1G1P7–STAD (DFS)

Open the STAD breakdown →